Literature DB >> 14573630

Characterization of chlamydial genital infection resulting from sexual transmission from male to female guinea pigs and determination of infectious dose.

Roger G Rank1, Anne K Bowlin, Ronald L Reed, Toni Darville.   

Abstract

A major problem in the study of chlamydial genital infections in animal models has been the use of varied doses of chlamydiae for infection in different laboratories. It is clearly desirable to use a dose which approximates that of natural sexual infection, but that dose to date has not been determined because of the inability of researchers to quantify chlamydiae in semen. Fortunately, sexual transmission of chlamydiae has been described for the guinea pig model of infection with the chlamydial agent of guinea pig inclusion conjunctivitis (GPIC). In this study, we undertook to determine the approximate infection dose in actual sexual transmission by comparing the kinetics of infection in female guinea pigs acquired via sexual contact to those of genital infections induced artificially with known quantities of chlamydiae. Groups of guinea pigs were infected intravaginally with 10(4), 10(3), 10(2), and 10(1) inclusion-forming units (IFU) of GPIC, and the kinetics of the infection were determined. Infection with 10(2) IFU produced infections with lower peak levels than those in animals receiving 10(4) or 10(3) IFU. Seventy percent of animals receiving 10(2) IFU became infected, while 100 and 79% of animals receiving 10(4) and 10(3) IFU, respectively, became infected. Animals receiving 10(2) IFU also had a longer incubation period. Of 19 animals that mated with infected males, 63.2% became infected, with an infection course which was not significantly different than that of the 10(2)-IFU-infected group. The data suggest that female guinea pigs received approximately 10(2) IFU by sexual transmission. Of interest was the observation that the guinea pigs infected by sexual transmission shed organisms for a significantly shorter time period than that of any group that was artificially infected. This result suggests that there may be factors associated with semen which passively transfer antimicrobial activity to the female or enhance the innate host response in the female. Immunization of females with an inactivated vaccine was also found to elicit a protective immune response against sexual challenge, demonstrating that the model can be used in the evaluation of possible vaccine candidates and/or methodologies. There is currently no other animal model available for any sexually transmitted disease in which the disease or the ability to prevent the disease may be studied in animals infected by the natural means.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14573630      PMCID: PMC219580          DOI: 10.1128/IAI.71.11.6148-6154.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Interrelationships among the characteristics of guinea-pig semen collected by electro-ejaculation.

Authors:  M Freund
Journal:  J Reprod Fertil       Date:  1969-08

Review 2.  Chlamydiae.

Authors:  J Schachter; H D Caldwell
Journal:  Annu Rev Microbiol       Date:  1980       Impact factor: 15.500

3.  Resistance to reinfection with a chlamydial agent (guinea pig inclusion conjunctivitis agent).

Authors:  A Ahmad; C R Dawson; C Yoneda; B Togni; J Schachter
Journal:  Invest Ophthalmol Vis Sci       Date:  1977-06       Impact factor: 4.799

4.  Quantitative culture of Chlamydia trachomatis: relationship of inclusion-forming units produced in culture to clinical manifestations and acute inflammation in urogenital disease.

Authors:  W M Geisler; R J Suchland; W L Whittington; W E Stamm
Journal:  J Infect Dis       Date:  2001-09-28       Impact factor: 5.226

5.  Infection of genital tract and transmission of ocular infection to newborns by the agent of guinea pig inclusion conjunctivitis.

Authors:  D T Mount; P E Bigazzi; A L Barron
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

6.  Expression of antimicrobial defensins in the male reproductive tract of rats, mice, and humans.

Authors:  Emmanuelle Com; Frédéric Bourgeon; Bertrand Evrard; Tomas Ganz; Daniel Colleu; Bernard Jégou; Charles Pineau
Journal:  Biol Reprod       Date:  2003-01       Impact factor: 4.285

7.  Cystitis associated with chlamydial infection of the genital tract in male guinea pigs.

Authors:  R G Rank; H J White; B L Soloff; A L Barron
Journal:  Sex Transm Dis       Date:  1981 Jul-Sep       Impact factor: 2.830

8.  Experimental infection of the marmoset genital tract with Chlamydia trachomatis.

Authors:  A P Johnson; C M Hetherington; M F Osborn; B J Thomas; D Taylor-Robinson
Journal:  Br J Exp Pathol       Date:  1980-06

9.  A new animal model for the study of Chlamydia trachomatis genital infections: infection of mice with the agent of mouse pneumonitis.

Authors:  A L Barron; H J White; R G Rank; B L Soloff; E B Moses
Journal:  J Infect Dis       Date:  1981-01       Impact factor: 5.226

10.  Experimental genital infection of male guinea pigs with the agent of guinea pig inclusion conjunctivitis and transmission to females.

Authors:  D T Mount; P E Bigazzi; A L Barron
Journal:  Infect Immun       Date:  1973-12       Impact factor: 3.441

View more
  19 in total

1.  Characterization of the Horizontal and Vertical Sexual Transmission of Chlamydia Genital Infections in a New Mouse Model.

Authors:  Sukumar Pal; Delia F Tifrea; Luis M de la Maza
Journal:  Infect Immun       Date:  2019-06-20       Impact factor: 3.441

2.  Phosphoproteomic analysis of the Chlamydia caviae elementary body and reticulate body forms.

Authors:  Derek J Fisher; Nancy E Adams; Anthony T Maurelli
Journal:  Microbiology       Date:  2015-05-21       Impact factor: 2.777

Review 3.  Animal models for studying female genital tract infection with Chlamydia trachomatis.

Authors:  Evelien De Clercq; Isabelle Kalmar; Daisy Vanrompay
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

4.  Guinea pig genital tract lipidome reveals in vivo and in vitro regulation of phosphatidylcholine 16:0/18:1 and contribution to Chlamydia trachomatis serovar D infectivity.

Authors:  Shradha Wali; Rishein Gupta; Jieh-Juen Yu; Adelphe Mfuh; Xiaoli Gao; M Neal Guentzel; James P Chambers; Sazaly Abu Bakar; Guangming Zhong; Bernard P Arulanandam
Journal:  Metabolomics       Date:  2016-03-08       Impact factor: 4.290

5.  Tumor necrosis factor alpha production from CD8+ T cells mediates oviduct pathological sequelae following primary genital Chlamydia muridarum infection.

Authors:  Ashlesh K Murthy; Weidang Li; Bharat K R Chaganty; Sangamithra Kamalakaran; M Neal Guentzel; J Seshu; Thomas G Forsthuber; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2011-05-02       Impact factor: 3.441

6.  Impact of azithromycin resistance mutations on the virulence and fitness of Chlamydia caviae in guinea pigs.

Authors:  Rachel Binet; Anne K Bowlin; Anthony T Maurelli; Roger G Rank
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

7.  Induction of partial immunity in both males and females is sufficient to protect females against sexual transmission of Chlamydia.

Authors:  C P O'Meara; C W Armitage; A Kollipara; D W Andrew; L Trim; M B Plenderleith; K W Beagley
Journal:  Mucosal Immunol       Date:  2015-12-09       Impact factor: 7.313

Review 8.  Immunopathogenesis of Chlamydial Infections.

Authors:  Ashlesh K Murthy; Weidang Li; Kyle H Ramsey
Journal:  Curr Top Microbiol Immunol       Date:  2018       Impact factor: 4.291

Review 9.  The guinea pig as a model of infectious diseases.

Authors:  Danielle J Padilla-Carlin; David N McMurray; Anthony J Hickey
Journal:  Comp Med       Date:  2008-08       Impact factor: 0.982

10.  C3H male mice with severe combined immunodeficiency cannot clear a urethral infection with a human serovar of Chlamydia trachomatis.

Authors:  Sukumar Pal; Annahita K Sarcon; Luis M de la Maza
Journal:  Infect Immun       Date:  2009-10-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.